Skip to content

Trial Summary

This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma.

Acronym:

MK-3475-716

ACTRN/NCT /ethics:

NCT03553836

Scientific title:

Safety and efficacy of pembrolizumab compared to placebo in resected high-risk stage II melanoma

Sponsor / Cooperative group:

Merck Sharp & Dohme Corp.

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeTreatment
PhasePhase III
Age Range12 years and older
SexBoth
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2018-09-12
Anticipated End Date2033-10-21

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorProfessor Michael Brown
Recruitment StatusRecruiting
HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Brian Stein
Recruitment StatusRecruiting